BE631713A - - Google Patents
Info
- Publication number
- BE631713A BE631713A BE631713DA BE631713A BE 631713 A BE631713 A BE 631713A BE 631713D A BE631713D A BE 631713DA BE 631713 A BE631713 A BE 631713A
- Authority
- BE
- Belgium
- Prior art keywords
- tetranitrate
- weight
- pentaerythrol
- therapeutic
- hydrochloride
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000000829 suppository Substances 0.000 claims description 7
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229960004782 chlordiazepoxide Drugs 0.000 claims description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 4
- 239000004593 Epoxy Substances 0.000 claims 2
- 150000002118 epoxides Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- FFEUJVKTVREMIG-UHFFFAOYSA-N C(C1=CC=CC=C1)S(=O)(=O)O.C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)S(=O)(=O)O.C1=CC=CC=C1 FFEUJVKTVREMIG-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004725 chlordiazepoxide hydrochloride Drugs 0.000 description 1
- DMLFJMQTNDSRFU-UHFFFAOYSA-N chlordiazepoxide hydrochloride Chemical compound Cl.O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 DMLFJMQTNDSRFU-UHFFFAOYSA-N 0.000 description 1
- 229940057026 chlordiazepoxide hydrochloride 25 mg Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- -1 glycerin glycerin fatty acids Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE631713A true BE631713A (enrdf_load_stackoverflow) |
Family
ID=200059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE631713D BE631713A (enrdf_load_stackoverflow) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE631713A (enrdf_load_stackoverflow) |
-
0
- BE BE631713D patent/BE631713A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2460667A1 (fr) | Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide | |
| CA2498260A1 (en) | Pharmaceutical formulations of modafinil | |
| FR2466248A1 (fr) | Derives d'agents anti-inflammatoires non steroides, procede de preparation et compositions pharmaceutiques les contenant | |
| CA2680433A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| FR2484832A1 (fr) | Composition pharmaceutique utile pour le traitement de l'allergie | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| FR2530468A1 (fr) | Composition analgesique et anti-inflammatoire contenant de l'ibuprofen | |
| FR2599254A1 (fr) | Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale. | |
| BG104568A (bg) | Фармацевтичен състав, съдържащ сибутрамин и орлистат | |
| EP0068998B1 (fr) | Aryl-1 aminométhyl-2 cyclopropanes carboxylates (Z), leur préparation et leur application en tant que médicaments utiles dans le traitement d'algies diverses | |
| BE1007024A5 (fr) | Compositions a activite agoniste des recepteurs analogues a 5ht1, selective. | |
| JPH0699310B2 (ja) | アセトアルデヒド解毒剤 | |
| BE631713A (enrdf_load_stackoverflow) | ||
| BE1007158A3 (fr) | Composition pharmaceutique a base d'une imidazolylcarbazolone destinee a l'adminstration rectale. | |
| LU85242A1 (fr) | Nouvelle association medicamenteuse | |
| EP0001947B1 (fr) | Dérivés de l'amino-2 thiazoline, procédé de préparation et compositions pharmaceutiques les contenant | |
| FR2547730A1 (fr) | Medicament hypolipidemiant contenant comme ingredient actif la d-3-acetoxy-cis-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepine-4(5h)-one ou un de ses sels d'addition d'acides acceptables en pharmacie | |
| FR2605222A1 (fr) | Agent therapeutique a base de nitrate de n-(2-hydroxyethyl) nicotinamide pour le traitement de troubles associes a l'ischemie cerebrale | |
| FR2691630A1 (fr) | Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1. | |
| BE620468A (enrdf_load_stackoverflow) | ||
| EP0287469B1 (fr) | Assocation renfermant à titre de principes actifs, un analgésique central et la forskoline | |
| CH640137A5 (fr) | Composition pharmaceutique contenant de la s-adenosyl-l-homocysteine. | |
| JP2001278786A (ja) | 高尿酸性疾患予防治療剤 | |
| BE623397A (enrdf_load_stackoverflow) | ||
| JPH01249720A (ja) | 座薬 |